Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Completed 5Terminated 3Withdrawn 1Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Plasma cell 1

Conditions

Melanoma 50Carcinoma, Non-Small-Cell Lung 12Neoplasms 11Neoplasm Metastasis 10Carcinoma, Renal Cell 7Skin Neoplasms 5Prostatic Neoplasms 4Ovarian Neoplasms 4Lung Neoplasms 4Glioblastoma 4Diabetes Mellitus, Insulin-Dependent, 12 4Carcinoma, Hepatocellular 4Brain Neoplasms 4Advanced Cancer 4Uveal Melanoma 3Triple Negative Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Small Cell Lung Carcinoma 3Recurrence 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Pancreatic Neoplasms 3Multiple Myeloma 3Lymphoma, Non-Hodgkin 3Lymphoma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Breast Neoplasms 3Waldenstrom Macroglobulinemia 2Sarcoma 2Myeloproliferative Disorders 2Lymphoma, Mantle-Cell 2

Interventions

Rituximab 66Cyclophosphamide 52fludarabine phosphate 26fludarabine 22Filgrastim 21Vincristine 19Methotrexate 19Melphalan 19Doxorubicin 18Radiotherapy 17Etoposide 17Prednisone 16Tacrolimus 15Whole-Body Irradiation 14Mycophenolic Acid 14Cytarabine 14Peripheral Blood Stem Cell Transplantation 13Gemcitabine 13Cyclosporine 13Antilymphocyte Serum 13Lenalidomide 12Busulfan 11Bortezomib 11Granulocyte Colony-Stimulating Factor 9Alemtuzumab 9sargramostim 8Dexamethasone 8Cord Blood Stem Cell Transplantation 8pembrolizumab 7ibritumomab tiuxetan 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Lymphoma × Ipilimumab × Clear all
NCT02681302 2026-04-03

CPIT001

Hackensack Meridian Health

Phase 1/2 Terminated
46 enrolled 13 charts
LymphoidPlasma cell

Lymphoma, Multiple Myeloma

NCT03013491 2025-06-17

PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

CytomX Therapeutics

Phase 1/2 Terminated
196 enrolled 28 charts
Lymphoid

Diabetes Mellitus, Insulin-Dependent, 12, Lymphoma, Neoplasms

NCT02675439 2021-12-30

Safety and Efficacy of MIW815 (ADU-S100) +/- Ipilimumab in Patients With Advanced/Metastatic Solid Tumors or Lymphomas

Chinook Therapeutics, Inc.

Phase 1 Terminated
47 enrolled
Lymphoid

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡